Nichi-Iko Set To Delist In March As Tamura Steps Down As CEO
Successor To Be Selected At Extraordinary General Meeting In February
After nearly two difficult years for Nichi-Iko Pharmaceutical, the firm has announced at it will be acquired by a private equity fund and delisted from the Toyko Stock Exchange in 2023 and its CEO will step down from his post.
You may also be interested in...
Down But Not Out: Nichi-Iko Hives Off Sagent, Exits North America
Seven years after it paid almost three quarters of a billion dollars for US-based Sagent, troubled Nichi-Iko is offloading the struggling business.
What’s Next? Five Things To Look Out For In March
Prepare for all the biggest industry actions and events in March 2023 with Generics Bulletin’s monthly column.
Who’s Hired? Nichi-Iko Looks To Sandoz For Fresh Leadership
Nichi-Iko has revealed its choice of new leadership, looking to Sandoz Japan for its next president and CEO. Meanwhile, Ethypharm and Krka have made fresh appointments in the UK and Centrient has named a new chief quality officer.